JPH09507237A - スッポンとカメの組成物 - Google Patents
スッポンとカメの組成物Info
- Publication number
- JPH09507237A JPH09507237A JP7518250A JP51825095A JPH09507237A JP H09507237 A JPH09507237 A JP H09507237A JP 7518250 A JP7518250 A JP 7518250A JP 51825095 A JP51825095 A JP 51825095A JP H09507237 A JPH09507237 A JP H09507237A
- Authority
- JP
- Japan
- Prior art keywords
- turtle
- composition
- turtles
- mice
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000270666 Testudines Species 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 6
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 6
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract description 5
- 210000000750 endocrine system Anatomy 0.000 claims abstract description 5
- 230000036039 immunity Effects 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 238000002512 chemotherapy Methods 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 229940100688 oral solution Drugs 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004820 blood count Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 51
- 230000000694 effects Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 23
- 241000700159 Rattus Species 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000000843 powder Substances 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 241001061264 Astragalus Species 0.000 description 7
- 235000006533 astragalus Nutrition 0.000 description 7
- 210000004233 talus Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 229960004766 estradiol valerate Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000007180 physiological regulation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 1
- 241000012186 Litura Species 0.000 description 1
- 241000270711 Malaclemys terrapin Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001482311 Trionychidae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229960003734 levamisole hydrochloride Drugs 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.5−95重量%のスッポンと95−5重量%のカメから成る、スッポンと カメの組成物(TT組成物)。 2.当業者に一般に知られている方法によって経口溶液、カプセルまたは適当 な服用形態に加工することができる、請求項1記載のスッポンとカメの組成物( TT組成物)。 3.(1)生きているスッポンとカメを少なくとも7日間食物を与えずに腸内の 汚物を除去した後、別々に液体窒素中で1cm下の大きさの粒子に粉砕し、 (2) 粒子を4%以下の水分を含有する粒子に凍結乾燥し、 (3) スッポンとカメの乾燥した粒子を均一に混合し、それらに液体窒素を噴霧 し、100メッシュ以上の大きさの粒子に粉砕し、 (4) 上記の工程から得たスッポンとカメの混合物を通常の方法によって油を除 去し、ついでその混合物を照射で殺菌することを包含する、スッポンとカメの組 成物(TT組成物)の製造法。 4.人間の免疫性を強化し、人間の中枢神経系、心臓血管系および内分泌系を 調整し、且つ化学療法を受けられる癌患者の白血球数を増加する、請求項1記載 のスッポンとカメの組成物(TT組成物)の使用。 5.滋養の有る強壮剤として食品に加える、請求項1記載のスッポンとカメの 組成物の健康のための使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94100050A CN1095619A (zh) | 1994-01-04 | 1994-01-04 | 龟鳖养生胶囊及其制备方法 |
| CN94100050.8 | 1994-01-04 | ||
| PCT/CN1995/000001 WO1995018625A1 (en) | 1994-01-04 | 1995-01-04 | The composition containing snapping turtle and tortoise, the preparation and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09507237A true JPH09507237A (ja) | 1997-07-22 |
| JP2972343B2 JP2972343B2 (ja) | 1999-11-08 |
Family
ID=5029414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7518250A Expired - Lifetime JP2972343B2 (ja) | 1994-01-04 | 1995-01-04 | スッポンとカメの組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5866160A (ja) |
| JP (1) | JP2972343B2 (ja) |
| KR (1) | KR100239946B1 (ja) |
| CN (2) | CN1095619A (ja) |
| AU (1) | AU1380195A (ja) |
| CA (1) | CA2180119C (ja) |
| WO (1) | WO1995018625A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1069525C (zh) * | 1996-10-30 | 2001-08-15 | 海南养生堂药业有限公司 | 含龟油和鳖油的组合物及其制备方法 |
| US6372261B1 (en) * | 2000-07-07 | 2002-04-16 | Pharmaceutical Industry Technology And Development Center | Process for producing Guilu ErXiangao |
| CN1241598C (zh) * | 2002-05-14 | 2006-02-15 | 朱建中 | 一种治疗牙周病的中药制剂、制备方法及应用 |
| IL157772A (en) | 2003-09-04 | 2016-06-30 | Bmr Solutions Ltd | Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis |
| CN1328984C (zh) * | 2004-12-22 | 2007-08-01 | 钟祥凤 | 甲鱼精制造法 |
| KR101334264B1 (ko) | 2010-11-26 | 2013-11-28 | 김용수 | 거북 추출물을 함유하는 피부질환의 개선 또는 치료용 약학적 조성물 |
| CN104147049A (zh) * | 2014-07-17 | 2014-11-19 | 扬州诺瑞药业有限公司 | 甲鱼胶囊的制备方法 |
| CN108835545A (zh) * | 2018-06-14 | 2018-11-20 | 内江市享寿水产品有限责任公司 | 一种方便酸菜甲鱼粥制作方法 |
| CN109007625A (zh) * | 2018-07-28 | 2018-12-18 | 河南松仟生物科技有限公司 | 一种提高免疫力和抗雾霾的保健食品及其制备方法 |
| CN109007511A (zh) * | 2018-07-28 | 2018-12-18 | 河南松仟生物科技有限公司 | 一种固体饮料及其制备方法和食用方法 |
| CN115232882B (zh) * | 2022-06-23 | 2024-06-04 | 湖南农业大学 | 一种中华鳖遗传性别连锁的snp标记及其引物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5675078A (en) * | 1979-11-22 | 1981-06-20 | Iwatani & Co | Preparation of snapping turtle powder |
| JPS571980A (en) * | 1980-06-04 | 1982-01-07 | Mitsubishi Electric Corp | Gamma-ray dose rate meter |
| JPS585020B2 (ja) * | 1980-12-25 | 1983-01-28 | 岩谷産業株式会社 | スツポン微粉末を主成分とする栄養強化食品 |
| JPS5953823B2 (ja) * | 1982-08-26 | 1984-12-27 | 岩谷産業株式会社 | スツポン粉末の製造法 |
| JPS63116642A (ja) * | 1986-11-04 | 1988-05-20 | Iwatani & Co | スツポン微粉末の製造方法 |
| CN1091960A (zh) * | 1993-03-05 | 1994-09-14 | 胡锴 | 龟鳖芦抗癌药 |
-
1994
- 1994-01-04 CN CN94100050A patent/CN1095619A/zh active Pending
-
1995
- 1995-01-04 CA CA002180119A patent/CA2180119C/en not_active Expired - Fee Related
- 1995-01-04 JP JP7518250A patent/JP2972343B2/ja not_active Expired - Lifetime
- 1995-01-04 US US08/669,322 patent/US5866160A/en not_active Expired - Lifetime
- 1995-01-04 KR KR1019960703594A patent/KR100239946B1/ko not_active Expired - Lifetime
- 1995-01-04 AU AU13801/95A patent/AU1380195A/en not_active Abandoned
- 1995-01-04 CN CN95190005A patent/CN1032951C/zh not_active Expired - Lifetime
- 1995-01-04 WO PCT/CN1995/000001 patent/WO1995018625A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR970700038A (ko) | 1997-01-08 |
| KR100239946B1 (ko) | 2000-02-01 |
| WO1995018625A1 (en) | 1995-07-13 |
| CN1095619A (zh) | 1994-11-30 |
| US5866160A (en) | 1999-02-02 |
| CA2180119C (en) | 2003-07-29 |
| CN1032951C (zh) | 1996-10-09 |
| AU1380195A (en) | 1995-08-01 |
| CA2180119A1 (en) | 1995-07-13 |
| JP2972343B2 (ja) | 1999-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8900639B2 (en) | Process for obtaining a rabbit skin comprising biological active substances | |
| CN102669466B (zh) | 一种21-42日龄肉鸭饲料及其制备方法 | |
| CN103598426B (zh) | 用于提高雏鸡生长性能的饲料添加剂及饲料 | |
| CN103749982A (zh) | 用于提高产鸡蛋产量的饲料、中药添加剂和制备方法 | |
| JPH09507237A (ja) | スッポンとカメの組成物 | |
| CN112569305A (zh) | 一种提高免疫力的香菇复合多糖组合物及其制备方法 | |
| JP2002125662A (ja) | 未失活酵素強化組成物 | |
| CN108813610B (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
| CN115191534A (zh) | 一种缓解疲劳的牛大力饮品及其制备方法 | |
| CN109170916A (zh) | 一种强身健体食品组合物及其制备方法 | |
| CN118416191B (zh) | 一种牡蛎肽粉组合物及其制备方法与应用 | |
| CN103877486A (zh) | 用于促升放化疗后白细胞数量的药物及其制备方法 | |
| CN114869953B (zh) | 一种抗疲劳增免疫治疗风湿的组合物及其制备方法 | |
| KR101911877B1 (ko) | 생약재 추출물을 유효성분으로 포함하는 관절염 개선용 건강기능식품 조성물 | |
| AU732706B2 (en) | Lipid-based immune modulator composition | |
| CN103719552B (zh) | 用于防治猪丹毒的饲料及其制备方法 | |
| CN115836702A (zh) | 一种具有提高免疫力功能的复合植物肽压片糖果及其制备方法 | |
| CN108619486B (zh) | 一种治疗皮肤病的软膏剂及其制备方法 | |
| JPH01304861A (ja) | ミミズ乾燥粉末の製法 | |
| AU2021102946A4 (en) | Chinese Herbal Medicine Complete Feed for Piglets and Preparation Method Thereof | |
| CN111358850A (zh) | 一种用于防治鸡大肠杆菌病的中药组合物及其制备方法 | |
| CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
| CN121128923A (zh) | 一种具有保肝活性的海参肽保健食品及其制备方法 | |
| JPS63112522A (ja) | トナカイの角からなる滋養強壮薬品 | |
| CN109043527A (zh) | 调节人体亚健康及提高免疫力的组合物与制备工艺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080827 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080827 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090827 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100827 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110827 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110827 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120827 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120827 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130827 Year of fee payment: 14 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |